Search results for "Drug resistance"

showing 10 items of 953 documents

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylatin…

2018

Patients with primary refractory or relapsed-acute myeloid leukemia (RR-AML), particularly older adults, have dismal outcomes and limited therapy options [1]. Given the tolerability of hypomethylat...

AdultMaleOncologyCancer Researchmedicine.medical_specialtyMyeloidAdolescentendocrine system diseasesmedicine.medical_treatmentHematopoietic stem cell transplantationRisk AssessmentYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTransplantation HomologousneoplasmsSurvival analysisAgedRetrospective StudiesAged 80 and overbusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisTransplantationLeukemia Myeloid AcuteLeukemiaTreatment Outcomemedicine.anatomical_structureOncologyTolerabilityHypomethylating agentDrug Resistance Neoplasmhypomethylating agent acute myeloid leukemia.FemaleNeoplasm Recurrence LocalbusinessLeukemia & Lymphoma
researchProduct

FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer

2014

<b><i>Purpose:</i></b> Fluoropyrimidines, oxaliplatin, irinotecan and targeted therapies represent the standard treatment of metastatic colorectal cancer. After failure of all these treatments, few options are available. In such chemorefractory patients the effect of triplet chemotherapy with bevacizumab (FOLFIRINOX bevacizumab) has never been investigated. <b><i>Patients and Methods:</i></b> 49 consecutive patients bearing unresectable metastatic colorectal cancer and who experienced failure to oxaliplatin- and irinotecan-based chemotherapy were treated with oxaliplatin (85 mg/m<sup>2</sup>), irinotecan (180 mg/m<sup>2</s…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsBevacizumabFOLFIRINOXColorectal cancerLeucovorinSalvage therapyAntibodies Monoclonal HumanizedIrinotecanInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesSurvival rateAgedNeoplasm StagingAged 80 and overSalvage Therapybusiness.industryLiver NeoplasmsGeneral MedicineMiddle AgedPrognosismedicine.diseasedigestive system diseasesOxaliplatinBevacizumabOxaliplatinSurvival RateIrinotecanOncologyDrug Resistance NeoplasmFluorouracilCamptothecinFemaleFluorouracilColorectal NeoplasmsbusinessFollow-Up Studiesmedicine.drugOncology
researchProduct

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015

Purpose Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accepted standard of care for patients with relapsed or refractory disease. This study evaluated the efficacy and tolerability of belinostat, a novel histone deacetylase inhibitor, as a single agent in relapsed or refractory PTCL. Patients and Methods Patients with confirmed PTCL who experienced progression after ≥ one prior therapy received belinostat 1,000 mg/m2 as daily 30-minute infusions on days 1 to 5 every 21 days. Central assessment of response used International Working Group criteria. Primary end point was overall response rate. Secondary end points included …

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsKaplan-Meier EstimateHydroxamic AcidsDisease-Free SurvivalDrug Administration Schedulechemistry.chemical_compoundRefractoryInternal medicineClinical endpointHumansMedicineInfusions IntravenousAgedAged 80 and overSulfonamidesbusiness.industryHistone deacetylase inhibitorLymphoma T-Cell PeripheralORIGINAL REPORTSMiddle Agedmedicine.diseaseLymphomaSurgeryHistone Deacetylase InhibitorsClinical trialTreatment OutcomePrior TherapyOncologyTolerabilitychemistryDrug Resistance NeoplasmFemaleNeoplasm Recurrence LocalbusinessBelinostatJournal of Clinical Oncology
researchProduct

PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy

2012

Soft tissue sarcomas are aggressive tumors representing <1% of all adult neoplasms. Aim of our study was to evaluate promyelocytic leukemia gene expression value as prognostic factor and as a factor predicting response to alkylating agents/antracycline-based first line therapy. One hundred eleven patients affected by locally advanced and metastatic soft tissue sarcoma were selected. PML expression was evaluated by immunohistochemical analysis in pathological samples and in the corresponding normal tissue from each case. PML immunohistochemical results were correlated with prognosis and with radiological response to alkylating agents/antracycline-based first line therapy. PML expression was …

AdultMaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical BiochemistryCellDown-RegulationSoft Tissue NeoplasmsPromyelocytic Leukemia ProteinLiposarcomaPleomorphic LiposarcomaYoung AdultPredictive Value of TestsInternal medicinemedicineHumansAnthracyclinesAntineoplastic Agents AlkylatingPathologicalAgedRetrospective StudiesAged 80 and overPMLbusiness.industryTumor Suppressor ProteinsSoft tissue sarcomaNuclear ProteinsSoft tissueSarcomaCell BiologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistrymedicine.anatomical_structuresoft tissue sarcomas; PMLDrug Resistance Neoplasmsoft tissue sarcomaImmunologyImmunohistochemistryFemaleSarcomabusinessTranscription Factors
researchProduct

Subregional Pathology of the Amygdala Complex and Entorhinal Region in Surgical Specimens From Patients With Pharmacoresistant Temporal Lobe Epilepsy

2000

The hippocampus, amygdala complex, and entorhinal region represent anatomically linked limbic structures of the mesiotemporal lobe. Chronic seizures and mnestic deficits in patients with pharmacoresistant mesial temporal lobe epilepsy (TLE) appear to correlate with distinct patterns of histopathological alterations in these areas. The complex anatomical organization of the amygdala and entorhinal region, however, render a detailed neuropathological evaluation of surgical specimens difficult. In this study, we present a combined cytoarchitectonical, pigmentarchitectonical, myelinarchitectonical, and immunohistochemical reconstruction of the amygdala, entorhinal region, and hippocampus from s…

AdultMalePathologymedicine.medical_specialtyAdolescentDrug ResistanceHippocampusAutopsyAmygdalaPathology and Forensic MedicineTemporal lobeCentral nervous system diseaseCellular and Molecular NeuroscienceEpilepsyBasal (phylogenetics)medicineEntorhinal CortexHumansGliosisSclerosisGeneral MedicineMiddle AgedAmygdalamedicine.diseaseTemporal LobeLobemedicine.anatomical_structureEpilepsy Temporal Lobenervous systemNeurologyChild PreschoolAnticonvulsantsFemaleNeurology (clinical)Psychologypsychological phenomena and processesJournal of Neuropathology &amp; Experimental Neurology
researchProduct

Detection of HIV type 1 non-B subtypes in Sicily, Italy.

2004

To evaluate the presence of HIV-1 non-B subtypes in Sicily, we sequenced and genotyped HIV-1 PR and RT regions of the pol gene using plasma from 169 HIV-1-infected adult patients. All samples were obtained from a study of antiretroviral-associated resistance mutations resulting in virological failure during highly active antiretroviral therapy (HAART). Eight (4.7%) patients had the non-B HIV-1 subtype including some circulating recombinant forms (CRFs). All of these individuals acquired the infection by heterosexual transmission. The detection of HIV-1 non-B strains was significantly associated with younger age of HIV-1 acquisition. Our findings indicate, for the first time, the presence of…

AdultMalePol genesYounger ageImmunologyMolecular Sequence DataHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeVirusVirologyAntiretroviral Therapy Highly ActiveDrug Resistance ViralmedicineHumansIn patientTreatment FailurebiologyAdult patientsvirus diseasesMiddle Agedbiology.organism_classificationAntiretroviral therapyVirologyGenes polInfectious DiseasesItalyLentivirusImmunologyMutationHIV-1RNA ViralFemaleAIDS research and human retroviruses
researchProduct

Genotyping and antifungal susceptibility of human subgingival Candida albicans isolates.

2002

Subgingival colonization by Candida albicans has been described in human immunodeficiency virus (HIV)-infected individuals, but subgingival isolates have scarcely been characterized, particularly with respect to genotype and antifungal susceptibility. A series of 29 subgingival strains of C. albicans isolated from nine HIV-infected individuals was typed by electrophoretic karyotyping and tested for susceptibility to fluconazole, itraconazole, the new investigational triazole posaconazole and amphotericin B. DNA typing showed genetic heterogeneity within subgingival isolates, as almost every individual harbored his/her own specific isolate. Genetic identity was usually demonstrated within or…

AdultMalePosaconazoleAntifungal AgentsItraconazoleDental PlaqueHIV InfectionsMicrobial Sensitivity TestsMicrobiologyPeriodontal pathogenGenetic HeterogeneityDrug Resistance FungalAmphotericin BGenotypeCandida albicansmedicineHumansCandida albicansDNA FungalMycological Typing TechniquesGeneral DentistryGenotypingFluconazolebiologyCell BiologyGeneral MedicineTriazolesbiology.organism_classificationVirologyCorpus albicansOtorhinolaryngologyKaryotypingFemaleItraconazoleFluconazolemedicine.drugArchives of oral biology
researchProduct

Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.

2014

ABSTRACT Background At diagnosis, identification of reliable biological indicators of prognosis to allow stratification of patients according to different risks is an important but still unresolved aspect in the treatment of Ewing sarcoma (EWS) patients. This study aimed to explore the role of miR-34A expression on prognosis of EWS patients. Patients and methods Specimens from 109 patients with non-metastatic EWS treated at the Rizzoli Institute with neoadjuvant chemotherapy (protocols ISG/SSGIII, EW-1, EW-2, EW-REN2, EW-REN3, EW-PILOT) and 17 metastases were studied. Sixty-eight patients (62%) remained disease-free and 41 (38%) relapsed (median follow-up: 67 months, range 9–241 months). Ex…

AdultMalePrognosiHydro-Lyasemedicine.medical_treatmentSarcoma EwingDisease-Free SurvivalCyclin D1medicineHumansCyclin D1Neoplasm Metastasisprognostic biomarkerNeoadjuvant therapyHydro-LyasesAged 80 and overTissue microarraybiologybusiness.industryProportional hazards modelMedicine (all)Ewing's sarcomaMicroRNAHematologyMiddle Agedmedicine.diseasePrognosisNeoadjuvant TherapyNeoplasm MetastasiGene Expression Regulation NeoplasticMicroRNAsKi-67 AntigenTreatment OutcomeOncologyDrug Resistance NeoplasmKi-67biology.proteinCancer researchKi-67ImmunohistochemistryFemaleSarcomacyclin D1; Ewing sarcoma; Ki-67; miR-34a; prognostic biomarkers; Adult; Aged 80 and over; Cyclin D1; Disease-Free Survival; Drug Resistance Neoplasm; Female; Gene Expression Regulation Neoplastic; Humans; Hydro-Lyases; Ki-67 Antigen; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Sarcoma Ewing; Treatment Outcome; Medicine (all)businessEwing sarcomamiR-34aHumanAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4

2008

We investigated the mechanisms involved in the resistance to cell death observed in epithelial cancers. Here, we identify that primary epithelial cancer cells from colon, breast and lung carcinomas express high levels of the antiapoptotic proteins PED, cFLIP, Bcl-xL and Bcl-2. These cancer cells produced interleukin-4 (IL-4), which amplified the expression levels of these antiapoptotic proteins and prevented cell death induced upon exposure to TRAIL or other drug agents. IL-4 blockade resulted in a significant decrease in the growth rate of epithelial cancer cells and sensitized them, both in vitro and in vivo, to apoptosis induction by TRAIL and chemotherapy via downregulation of the antia…

AdultMaleProgrammed cell deathLung NeoplasmsTime Factorsapoptosis interleukin-4 cancer stem cells cancer chemiotherapy cytokinesCASP8 and FADD-Like Apoptosis Regulating Proteinbcl-X ProteinAntineoplastic AgentsApoptosisBreast NeoplasmsBiologyTNF-Related Apoptosis-Inducing LigandTumor Cells CulturedmedicineHumansAutocrine signallingMolecular BiologyInterleukin 4AgedCell ProliferationSettore MED/04 - Patologia GeneraleCell DeathDose-Response Relationship DrugCell growthCarcinomaIntracellular Signaling Peptides and ProteinsAntibodies MonoclonalInterleukin-4 Receptor alpha SubunitCorrectionCancerCell BiologyMiddle AgedPhosphoproteinsmedicine.diseaseUp-RegulationCell biologyAutocrine CommunicationProto-Oncogene Proteins c-bcl-2Drug Resistance NeoplasmApoptosisColonic NeoplasmsCancer cellFemaleInterleukin-4Interleukin-4 Cancer stem cellsSignal transductionApoptosis Regulatory ProteinsSignal Transduction
researchProduct

Monitoring changes in anti-tuberculosis treatment: associated factors determined at the time of diagnosis

2013

OBJECTIVES: To determine predictive factors for changes in standard anti-tuberculosis chemotherapy at the time of diagnosis. METHODS: A prospective study was performed among tuberculosis (TB) patients treated at specialised centres during 2008-2009. Treatment outcome was monitored per standard guidelines. Treatment was considered successful if the patient was cured or completed treatment. Factors associated with treatment modification were analysed at the bivariate and multivariate levels using logistic regression. RESULTS: A total of 427 patients were included in the study. The initial standard treatment regimen was retained for 249 patients (58.3%), extended to 9 months for 36 (8.4%) and …

AdultMalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyTime FactorsMultivariate analysisTuberculosisAntitubercular AgentsComorbiditySex FactorsDrug Resistance Multiple BacterialTuberculosis Multidrug-ResistantOdds RatioHumansTuberculosisMedicineProspective StudiesProspective cohort studyDrug Substitutionbusiness.industryStandard treatmentRemission InductionAge FactorsOdds ratioMiddle Agedmedicine.diseaseComorbidityRegimenLogistic ModelsTreatment OutcomeInfectious DiseasesSpainMultivariate AnalysisPractice Guidelines as TopicSputumDrug Therapy CombinationFemaleGuideline Adherencesense organsmedicine.symptombusinessThe International Journal of Tuberculosis and Lung Disease
researchProduct